查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020128

多發性硬化症治療市場：規模、佔有率和成長：按類型、應用和地區分類的洞察，2026-2034 年預測

Multiple Sclerosis Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 165 Pages | 商品交期: 請詢問到貨日

價格

多發性硬化症治療市場的成長要素

全球多發性硬化症（MS）治療市場預計在2025年達到210.7億美元，2026年成長至229.5億美元，到2034年達到532億美元，在預測期（2026-2034年）內複合年成長率高達11.08%。這一快速成長反映了該疾病患病率的上升、藥物研發的持續創新以及全球治療可及性的提高。

預計到2025年，北美將引領市場，佔48.51%的市場。這主要得益於北美高額的醫療保健支出、先進的研究基礎設施以及強力的公眾意識宣傳活動。

市場概覽

多發性硬化症（MS）是一種慢性免疫介導性疾病，會影響中樞神經系統，導致發炎、去髓鞘化和神經退化。全球患者人數從2013年的230萬急劇增加到2020年的280萬，因此對有效治療方法的需求日益成長。

該市場的主要驅動力是疾病修正治療（DMT）需求的不斷成長、診斷率的提高以及治療途徑的擴大。政府和醫療機構對宣傳活動的積極支持以及對研究的資助也促進了市場的持續成長。

市場趨勢

單株抗體的應用日益廣泛

塑造市場格局的關鍵趨勢之一是單株抗體在多發性硬化症治療中的應用日益廣泛。這些治療方法具有標靶作用機轉、療效更佳、復發率更低等優點。諸如奧克瑞珠單抗（Ocrevus）等藥物已獲得廣泛認可，並推動了強勁的銷售成長。

製藥公司正致力於開發先進的生物製藥和抗體療法，預計這些療法將在預測期內重新定義治療通訊協定並改善患者的治療效果。

市場成長要素

增加研發投資

對研發投入的增加是市場成長的主要驅動力。大型製藥企業正大力投資臨床試驗和產品線開發，以推出安全性和有效性更高的創新治療方法。

目前正在研發的幾種藥物針對不同的作用機制，有可能在未來幾年內顯著改變多發性硬化症 (MS) 的治療策略。

政府支持及宣傳計劃

政府措施和宣傳宣傳活動在市場拓展中發揮著至關重要的作用。 「多發性硬化症宣傳月」等計畫以及美國國家多發性硬化症協會等組織的資助，都在促進早期診斷和治療。

已開發地區有利的報銷政策進一步促進了患者獲得昂貴治療方法，從而推動了整體市場成長。

抑制因子

治療費用高昂

儘管取得了一些進展，但多發性硬化症治療的高成本仍然是一項重大挑戰。疾病修正治療每年的費用可能高達9.4萬美元，這限制了患者的獲得，尤其是在中低收入國家。

自付費用增加和保險限制可能導致治療依從性下降，可能對市場成長產生負面影響。

市場區隔分析

藥物類別

在市場區隔中，這些藥物分為免疫調節劑、免疫抑制劑、干擾素和其他藥物。

  • 由於免疫調節藥物療效顯著且新產品不斷推出，因此佔市場主導地位。
  • 「其他」部分（包括單株抗體）由於其在抑制復發方面的有效性，佔了很大的佔有率（到 2026 年將達到 47.63%）。

透過行政途徑

  • 注射藥物領域，在注射療法核准不斷增加的推動下，預計將在 2026 年佔 57.96% 的市場佔有率，引領市場。
  • 由於便利性的提高和新產品的推出，預計口服藥物市場將呈現最高的成長率。

透過分銷管道

到2026年，醫院藥局將以48.94%的市場佔有率引領市場，主要得益於醫保報銷計畫和先進治療方法的普及。而線上藥局則因數位化的進步和宅配的興起而快速發展。

區域趨勢

  • 北美：在強大的研發和宣傳活動的推動下，預計到 2025 年，市場規模將達到 102.2 億美元。
  • 歐洲：預計到 2025 年將達到 59.3 億美元，這得益於報銷措施和不斷上升的發病率。
  • 亞太地區：預計到 2025 年將達到 27.7 億美元，這主要得益於醫療基礎設施的改善和夥伴關係的擴大。
  • 拉丁美洲和中東及非洲：由於醫療保健投資的增加，這些新興地區呈現穩定成長態勢。

主要企業

市場競爭異常激烈，主要企業正致力於創新與產品組合拓展。主要企業包括：

  • Biogen
  • 輝瑞
  • F. Hoffmann-La Roche Ltd.
  • NovartisAG
  • Sanofi
  • Merck & Co., Inc.

這些公司正積極尋求合作、收購和產品發布，以鞏固其市場地位。

產業趨勢

近期進展如下：

  • FDA核准生物相似藥「Tyruko」（2023年）
  • 大型製藥企業之間的策略聯盟
  • 推出新的口服和注射療法
  • 透過標靶創新治療機制來拓展臨床研發管線

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 多發性硬化症盛行率－按主要國家和地區分類，2025/2025 年
  • 監管趨勢－按主要國家和地區分類
  • 主要企業專利摘要
  • 管道分析和研發投資
  • 新產品發布：按主要企業分類
  • 產業重大發展－併購與合作
  • 摘要：多發性硬化症的治療費用
  • 新冠疫情對市場的影響

第5章：全球市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按藥物類別分類
    • 免疫調節藥物
    • 免疫抑制劑
    • 干擾素
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 注射
      • 肌肉內部
      • 皮下
      • 靜脈
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章：拉丁美洲市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第10章：中東與非洲市場分析、洞察與預測（2021-2034年）

  • 國家
    • 南非
    • GCC
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Biogen
    • Teva Pharmaceutical Industries Ltd.
    • Merck KGaA
    • Sanofi
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Janssen Pharmaceuticals, Inc.（Johnson & Johnson Corporation）
    • Bristol-Myers Squibb Company
Product Code: FBI100386

Growth Factors of multiple sclerosis drugs Market

The global multiple sclerosis drugs market was valued at USD 21.07 billion in 2025 and is projected to grow to USD 22.95 billion in 2026, reaching USD 53.20 billion by 2034, registering a strong CAGR of 11.08% during the forecast period (2026-2034). The rapid growth reflects increasing disease prevalence, continuous innovation in drug development, and improved access to treatment globally.

North America dominated the market in 2025, accounting for a 48.51% share, supported by high healthcare spending, advanced research infrastructure, and strong awareness initiatives.

Market Overview

Multiple sclerosis (MS) is a chronic immune-mediated disease affecting the central nervous system, leading to inflammation, demyelination, and neurodegeneration. The global patient pool has increased significantly, rising from 2.3 million in 2013 to 2.8 million in 2020, which has intensified the demand for effective therapies.

The market is primarily driven by the rising need for disease-modifying therapies (DMTs), increasing diagnosis rates, and expanding treatment accessibility. Governments and healthcare organizations are actively supporting awareness and funding research, contributing to sustained market expansion.

Market Trends

Rising Adoption of Monoclonal Antibodies

A key trend shaping the market is the increasing use of monoclonal antibodies for MS treatment. These therapies offer targeted mechanisms, improved efficacy, and reduced relapse rates. Drugs such as Ocrevus have gained significant traction, contributing to strong revenue growth.

Pharmaceutical companies are focusing on developing advanced biologics and antibody-based therapies, which are expected to redefine treatment protocols and improve patient outcomes over the forecast period.

Market Growth Drivers

Increasing R&D Investments

The growing emphasis on research and development is a major driver of market growth. Leading pharmaceutical companies are investing heavily in clinical trials and pipeline development to introduce innovative therapies with better safety and efficacy profiles.

Several drugs under development target different mechanisms of action, which could significantly transform MS treatment strategies in the coming years.

Government Support and Awareness Programs

Government initiatives and awareness campaigns are playing a vital role in market expansion. Programs such as Multiple Sclerosis Awareness Month and funding by organizations like the National MS Society are improving early diagnosis and treatment adoption.

Favorable reimbursement policies in developed regions further support patient access to high-cost therapies, boosting overall market growth.

Restraining Factors

High Cost of Treatment

Despite advancements, the high cost of MS drugs remains a significant challenge. Disease-modifying therapies can cost up to USD 94,000 annually, limiting accessibility, especially in low- and middle-income countries.

Rising out-of-pocket expenses and insurance restrictions can lead to reduced treatment adherence, negatively impacting market growth.

Market Segmentation Analysis

By Drug Class

The market is segmented into immunomodulators, immunosuppressants, interferons, and others.

  • Immunomodulators dominate due to high efficacy and continuous product launches.
  • The "others" segment, including monoclonal antibodies, held a significant share (47.63% in 2026) due to their effectiveness in reducing relapses.

By Route of Administration

  • The injection segment dominated with a 57.96% share in 2026, driven by increasing approvals of injectable therapies.
  • The oral segment is expected to grow at the fastest rate due to convenience and rising product launches.

By Distribution Channel

Hospital pharmacies led the market with a 48.94% share in 2026, supported by reimbursement policies and advanced treatment availability. Online pharmacies are witnessing rapid growth due to increasing digital adoption and home delivery trends.

Regional Insights

  • North America: Valued at USD 10.22 billion in 2025, driven by strong R&D and awareness initiatives.
  • Europe: Accounted for USD 5.93 billion in 2025, supported by reimbursement policies and rising prevalence.
  • Asia Pacific: Reached USD 2.77 billion in 2025, with growth fueled by improving healthcare infrastructure and partnerships.
  • Latin America and Middle East & Africa: Emerging regions showing steady growth due to increasing healthcare investments.

Key Companies

The market is highly competitive, with major players focusing on innovation and portfolio expansion. Leading companies include:

  • Biogen
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Sanofi
  • Merck & Co., Inc.

These companies are actively engaged in collaborations, acquisitions, and product launches to strengthen their market position.

Industry Developments

Recent developments include:

  • FDA approval of biosimilar drug Tyruko (2023)
  • Strategic collaborations between major pharmaceutical firms
  • Launch of new oral and injectable therapies
  • Expansion of clinical pipelines targeting innovative treatment mechanisms

Conclusion

The multiple sclerosis drugs market is poised for robust growth, expanding from USD 21.07 billion in 2025 to USD 53.20 billion by 2034. This growth is driven by increasing disease prevalence, strong R&D investments, and advancements in biologics such as monoclonal antibodies. While high treatment costs remain a key challenge, supportive government initiatives, improved awareness, and continuous innovation are expected to enhance accessibility and treatment outcomes. Overall, the market presents significant opportunities for pharmaceutical companies to develop cost-effective and advanced therapies, ensuring sustained growth during the forecast period.

Segmentation By Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Injection
    • Intramuscular
    • Subcutaneous
    • Intravenous

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (By Drug Class, by Route of Administration, by Distribution Channel, and by Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • South Africa
    • GCC
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Multiple Sclerosis - For Key Countries/Regions, 2025/2025
  • 4.2. Regulatory Scenario - For Key Countries/Regions
  • 4.3. Patent Snapshot, By Key Players
  • 4.4. Pipeline Analysis & R&D Investments
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments - Mergers, Acquisitions and Partnerships
  • 4.7. Overview: Multiple Sclerosis Treatment Cost
  • 4.8. Impact of COVID-19 on the Market

5. Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Immunomodulators
    • 5.1.2. Immunosuppressants
    • 5.1.3. Interferons
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Injection
      • 5.2.2.1. Intramuscular
      • 5.2.2.2. Subcutaneous
      • 5.2.2.3. Intravenous
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Immunomodulators
    • 6.1.2. Immunosuppressants
    • 6.1.3. Interferons
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Injection
      • 6.2.2.1. Intramuscular
      • 6.2.2.2. Subcutaneous
      • 6.2.2.3. Intravenous
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail Pharmacy
    • 6.3.3. Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Immunomodulators
    • 7.1.2. Immunosuppressants
    • 7.1.3. Interferons
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Injection
      • 7.2.2.1. Intramuscular
      • 7.2.2.2. Subcutaneous
      • 7.2.2.3. Intravenous
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Immunomodulators
    • 8.1.2. Immunosuppressants
    • 8.1.3. Interferons
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Injection
      • 8.2.2.1. Intramuscular
      • 8.2.2.2. Subcutaneous
      • 8.2.2.3. Intravenous
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. China
    • 8.4.2. India
    • 8.4.3. Japan
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Immunomodulators
    • 9.1.2. Immunosuppressants
    • 9.1.3. Interferons
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Injection
      • 9.2.2.1. Intramuscular
      • 9.2.2.2. Subcutaneous
      • 9.2.2.3. Intravenous
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Immunomodulators
    • 10.1.2. Immunosuppressants
    • 10.1.3. Interferons
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Injection
      • 10.2.2.1. Intramuscular
      • 10.2.2.2. Subcutaneous
      • 10.2.2.3. Intravenous
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. South Africa
    • 10.4.2. GCC
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Biogen
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck KGaA
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Novartis AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. F. Hoffmann-La Roche Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Pfizer Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bristol-Myers Squibb Company
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2021-2034
  • Table 4: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2021-2034
  • Table 9: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2021-2034
  • Table 14: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2021-2034
  • Table 19: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2021-2034
  • Table 24: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2021-2034
  • Table 29: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Multiple Sclerosis Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Multiple Sclerosis Drugs Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 7: North America Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 8: North America Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Multiple Sclerosis Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Multiple Sclerosis Drugs Market Value Share (%), By Country, 2025
  • Figure 14: Europe Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 15: Europe Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 16: Europe Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 23: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 24: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 31: Latin America Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 32: Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 39: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 40: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2025
  • Figure 52: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Multiple Sclerosis Drugs Market Share (%), By Company, 2025